Ipsen Enters Exclusive Licensing Deal for Simcere Zaiming's Oncology Drug Candidate

02:41 AM EST, 12/22/2025 (MT Newswires) -- Ipsen (IPN.PA) said Monday that it signed an exclusive licensing deal for Simcere Zaiming's antibody drug conjugate, SIM0613, a potential cancer therapy. The deal will see Simcere Zaiming receive up to $1.06 billion in upfront, development payments, as well as for regulatory, commercial milestones, and tiered sales royalties, subject to development and regulatory clearances. Meanwhile, the French biopharmaceutical company will obtain manufacturing rights, as well as take over regulatory submissions and other preparation activities for an early-stage trial of SIM0613 outside Greater China. The phase 1 clinical development of SIM0613 is expected in the second half of 2026.